Home    Back

Target Gene/Pathway💬 Info on mouse-over

e.g. Sirolimus, Adalimumab, MAP2K

ABCDEFGH I JKLMNOPQRSTUVWXYZother

65 / 286 pathways

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related		 KEGG GENES KEGG DRUG DrugBank Disease ID
1 Adipocytokine signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
2 African trypanosomiasis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
3 AGE-RAGE signaling pathway in diabetic complications 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
4 Allograft rejection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
5 Alzheimer disease 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
6 Amoebiasis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
7 Amyotrophic lateral sclerosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
8 Antifolate resistance 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
9 Antigen processing and presentation 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
10 Apoptosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
11 Asthma 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
12 C-type lectin receptor signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
13 Chagas disease 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
14 Coronavirus disease - COVID-19 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
15 Cytokine-cytokine receptor interaction 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
16 Dilated cardiomyopathy 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
17 Epstein-Barr virus infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
18 Fc epsilon RI signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
19 Fluid shear stress and atherosclerosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
20 Graft-versus-host disease 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
21 Hematopoietic cell lineage 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
22 Hepatitis B 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
23 Hepatitis C 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
24 Herpes simplex virus 1 infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
25 Human cytomegalovirus infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
26 Human immunodeficiency virus 1 infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
27 Human papillomavirus infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
28 Human T-cell leukemia virus 1 infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
29 Hypertrophic cardiomyopathy 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
30 IL-17 signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
31 Inflammatory bowel disease 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
32 Influenza A 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
33 Insulin resistance 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
34 Legionellosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
35 Leishmaniasis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
36 Malaria 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
37 MAPK signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
38 mTOR signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
39 Natural killer cell mediated cytotoxicity 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
40 Necroptosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
41 NF-kappa B signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
42 NOD-like receptor signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
43 Non-alcoholic fatty liver disease 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
44 Osteoclast differentiation 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
45 Pathogenic Escherichia coli infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
46 Pathways of neurodegeneration - multiple diseases 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
47 Pertussis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
48 Prion disease 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
49 Proteoglycans in cancer 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
50 Rheumatoid arthritis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
51 RIG-I-like receptor signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
52 Salmonella infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
53 Shigellosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
54 Sphingolipid signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
55 Systemic lupus erythematosus 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
56 T cell receptor signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
57 TGF-beta signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
58 TNF signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
59 Toll-like receptor signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
60 Toxoplasmosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
61 Tuberculosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
62 Type I diabetes mellitus 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
63 Type II diabetes mellitus 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
64 Viral protein interaction with cytokine and cytokine receptor 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
65 Yersinia infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬

Back to top